Compare Novo Nordisk A/S (NVO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Nuscale Power Corporation — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while Nuscale Power Corporation trades at $7.18 (market cap $3.00B). The key difference: Novo Nordisk A/S is far larger — about 55.1× Nuscale Power Corporation's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Nuscale Power Corporation for 29 Days on average.
| NVO | SMR | |
|---|---|---|
Market Cap | $165.31B | $3.00B |
Volume | 11,432,838 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $63.98 | $53.43 |
52-Week Low | $35.29 | $7.32 |
Typical Hold Time | 116 Days | 29 Days |
Enterprise Value | $179.56B | $1.93B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
SMR trades at $7.145, down 6.84% on the day, reflecting ongoing investor concerns. The stock is technically bearish with moving averages signaling a downtrend, while fundamentals show severe losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Recent news highlights a Pomerantz law firm investigation into the company, adding to headwinds despite some analyst optimism.
The outlook remains high-risk; while 50% of analysts rate it a buy with a $11.25 consensus target, persistent losses, cash burn, and competitive pressures in the nuclear SMR space pose significant challenges. Upside depends on successful commercialization, but current financials and sentiment suggest caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
